Stentys has announced that its Self-Apposing stent has been implanted more than 10,000 times in patients worldwide. A company press release reports that this milestone further illustrates the popularity of Stentys’ technology among cardiologists in Europe and a growing number of regions globally. It adds that the stent solves the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents.
According to the press release, the Self-Apposing stent was first implanted during a “first-in-man” study in 2007. Since then, Stentys has enrolled more than 2,000 patients in clinical evaluations and conducted nine international clinical trials that have demonstrated the benefits of Self-Apposing technology over conventional options. The company has expanded marketing in Europe, the Middle East, Asia and South America, and is currently expecting approval of its sirolimus-eluting stent in Europe before year end.
“The 10,000th stent implanted represents a major milestone in the company’s history,” said Gonzague Issenmann, CEO and co-founder of Stentys. “We look forward to educating an even greater number of cardiologists and continuing our expansion to the benefit of all the patients worldwide that cannot be optimally treated with conventional balloon expandable stents.”